Navigation Links
NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults
Date:11/30/2009

ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

This study enrolled 467 older adults in a three-arm study at six different sites located within the United States. In addition to evaluating hemagglutinin inhibition (HAI) responses, anti-neuraminidase and cell-mediated immune responses are also being examined. Previous studies have shown that VLP-based flu vaccines drive strong neuraminidase inhibition (NAI) antibody titers and T-cell responses, indicating the potential for broader immunologic responses particularly in older adults.

"With the rapid completion of enrollment in this clinical trial as well as the first part of our H1N1 vaccine study in Mexico announced previously, we are on track to report results from our two most advanced clinical programs during the first quarter of next year," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "If results from the seasonal flu vaccine study are positive, we will be able to advance this program into Phase III clinical testing as early as 2010."

Seasonal Influenza

Seasonal influenza infects between 5 percent and 20 percent of the world's population and kills between 250,000 and 500,000 people each year. In the United States, the Centers for Disease Control and Prevention estimates th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Prices Public Offering of Common Stock
2. NOVAVAX Completes First Stage of Enrollment in Pivotal H1N1 Influenza Vaccine Study in the Country of Mexico
3. Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call
4. NOVAVAX to Present at Oppenheimer 20th Annual Healthcare Conference
5. Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
6. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
7. Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program
8. Novavax CEO to Present at the World Vaccine Congress 2009, Lyon, France
9. Novavax Announces Board of Director Changes
10. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
11. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... in U.S. dollars, QUEBEC CITY, May 7 /PRNewswire-FirstCall/ ... a global biopharmaceutical company focused on,endocrinology and oncology, today ... March 31, 2008., First Quarter 2008 Highlights, ... trial of the Phase 3 program ...
... 1Q08 -- -- 1Q08 Net ... $0.12 versus 1Q07 Diluted EPS $.10 on 11.6 Million ... Additional Shares --, NEW ... company dedicated to,improving health through the development, manufacture and commercialization,of a broad range ...
... potential as a super material is blighted by the ... form of an unprepossessing pile of sooty black mess in ... University of Warwicks Department of Chemistry have found a way ... highly sensitive ready made electric circuit. , The research has ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 2American Oriental Bioengineering Reports First Quarter 2008 Financial Results 3American Oriental Bioengineering Reports First Quarter 2008 Financial Results 4American Oriental Bioengineering Reports First Quarter 2008 Financial Results 5American Oriental Bioengineering Reports First Quarter 2008 Financial Results 6American Oriental Bioengineering Reports First Quarter 2008 Financial Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 8Nanotube production leaps from sooty mess in test tube to ready formed chemical microsensors 2
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... October 2011 - Genomatix is among the 41 partners ... Commission as a high impact project within its seventh ... sequencing data analysis and the development of an intuitive ... researchers within and outside the consortium. "To be ...
... that can strikingly reduce the number of risky diagnostic procedures ... to be introduced into clinical practice. The test can be ... who have been identified as being at high risk for ... study published online today in the journal Genetics in ...
... (UC Santa Barbara) Making waves as the ... a single layer of Carbon atoms has nonetheless ... be practical for innovative electronics applications. Researchers at UC ... quality graphene in a controlled manner that may pave ...
Cached Biology News:Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 2Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 3New method of growing high-quality graphene promising for next-gen technology 2New method of growing high-quality graphene promising for next-gen technology 3